ArriVent Biopharma Presents Initial Phase 1 Data for ARR-217 in Advanced Solid Tumors

• ArriVent Biopharma presented initial Phase 1 data for ARR-217 in 123 patients, including 113 with colorectal cancer.
• Grade 3 or higher treatment-related adverse events affected 30.1% of patients; serious treatment-related adverse events occurred in 19.5%.
• Treatment-related adverse events led to discontinuation in 0.8% of patients; no interstitial lung disease was reported.
• The maximum tolerated dose was not reached during dose escalation; one patient experienced dose-limiting toxicity at 8 mg/kg.
• Ongoing Phase 1b dose optimization in colorectal cancer is evaluating 5 mg/kg versus 6 mg/kg.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.